» Articles » PMID: 37200815

Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib

Overview
Specialty Biochemistry
Date 2023 May 18
PMID 37200815
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that expand dramatically in many cancer patients. This expansion contributes to immunosuppression in cancer and reduces the efficacy of immune-based cancer therapies. One mechanism of immunosuppression mediated by MDSCs involves production of the reactive nitrogen species peroxynitrite (PNT), where this strong oxidant inactivates immune effector cells through destructive nitration of tyrosine residues in immune signal transduction pathways. As an alternative to analysis of nitrotyrosines indirectly generated by PNT, we used an endoplasmic reticulum (ER)-targeted fluorescent sensor termed PS3 that allows direct detection of PNT produced by MDSCs. When the MDSC-like cell line MSC2 and primary MDSCs from mice and humans were treated with PS3 and antibody-opsonized TentaGel microspheres, phagocytosis of these beads led to production of PNT and generation of a highly fluorescent product. Using this method, we show that splenocytes from a EMT6 mouse model of cancer, but not normal control mice, produce high levels of PNT due to elevated numbers of granulocytic (PMN) MDSCs. Similarly, peripheral blood mononuclear cells (PBMCs) isolated from blood of human melanoma patients produced substantially higher levels of PNT than healthy human volunteers, coincident with higher peripheral MDSC levels. The kinase inhibitor dasatinib was found to potently block the production of PNT both by inhibiting phagocytosis in vitro and by reducing the number of granulocytic MDSCs in mice in vivo, providing a chemical tool to modulate the production of this reactive nitrogen species (RNS) in the tumor microenvironment.

Citing Articles

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.

He S, Zheng L, Qi C Mol Cancer. 2025; 24(1):5.

PMID: 39780248 PMC: 11707952. DOI: 10.1186/s12943-024-02208-3.


Targeting Myeloid-Derived Suppressor Cells via Dual-Antibody Fluorescent Nanodiamond Conjugate.

Angell C, Lapurga G, Sun S, Johnson C, Savardekar H, Rampersaud I Nanomaterials (Basel). 2024; 14(18).

PMID: 39330666 PMC: 11434946. DOI: 10.3390/nano14181509.


Tumor-associated CD8T cell tolerance induced by erythroid progenitor cells.

Fan X, Peng H, Wang X, Sun Y, Dong Y, Zhou J Front Immunol. 2024; 15:1381919.

PMID: 38799424 PMC: 11116624. DOI: 10.3389/fimmu.2024.1381919.

References
1.
Pawlicki M, Collins H, Denning R, Anderson H . Two-photon absorption and the design of two-photon dyes. Angew Chem Int Ed Engl. 2009; 48(18):3244-66. DOI: 10.1002/anie.200805257. View

2.
Montero A, Diaz-Montero C, Deutsch Y, Hurley J, Koniaris L, Rumboldt T . Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2011; 132(1):215-23. PMC: 3697917. DOI: 10.1007/s10549-011-1889-0. View

3.
Yang Y, Zhao Q, Feng W, Li F . Luminescent chemodosimeters for bioimaging. Chem Rev. 2012; 113(1):192-270. DOI: 10.1021/cr2004103. View

4.
Feng S, Cheng X, Zhang L, Lu X, Chaudhary S, Teng R . Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proc Natl Acad Sci U S A. 2018; 115(40):10094-10099. PMC: 6176562. DOI: 10.1073/pnas.1800695115. View

5.
Hoechst B, Ormandy L, Ballmaier M, Lehner F, Kruger C, Manns M . A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008; 135(1):234-43. DOI: 10.1053/j.gastro.2008.03.020. View